ES2962711T3 - Métodos para aumentar la eficacia de la reparación dirigida por homología (HDR) en el genoma celular - Google Patents
Métodos para aumentar la eficacia de la reparación dirigida por homología (HDR) en el genoma celular Download PDFInfo
- Publication number
- ES2962711T3 ES2962711T3 ES17832436T ES17832436T ES2962711T3 ES 2962711 T3 ES2962711 T3 ES 2962711T3 ES 17832436 T ES17832436 T ES 17832436T ES 17832436 T ES17832436 T ES 17832436T ES 2962711 T3 ES2962711 T3 ES 2962711T3
- Authority
- ES
- Spain
- Prior art keywords
- cell
- hdr
- nuclease
- sequence
- cas9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437042P | 2016-12-20 | 2016-12-20 | |
| PCT/US2017/067569 WO2018119060A1 (en) | 2016-12-20 | 2017-12-20 | Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2962711T3 true ES2962711T3 (es) | 2024-03-20 |
Family
ID=61006349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17832436T Active ES2962711T3 (es) | 2016-12-20 | 2017-12-20 | Métodos para aumentar la eficacia de la reparación dirigida por homología (HDR) en el genoma celular |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230193321A1 (enExample) |
| EP (2) | EP3559230B1 (enExample) |
| JP (3) | JP2020510443A (enExample) |
| KR (2) | KR20190095412A (enExample) |
| CN (2) | CN110300803B (enExample) |
| ES (1) | ES2962711T3 (enExample) |
| WO (1) | WO2018119060A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| EP3353296B1 (en) | 2015-09-24 | 2020-11-04 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| US11597924B2 (en) | 2016-03-25 | 2023-03-07 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| WO2017180694A1 (en) | 2016-04-13 | 2017-10-19 | Editas Medicine, Inc. | Cas9 fusion molecules gene editing systems, and methods of use thereof |
| EP3559230B1 (en) | 2016-12-20 | 2023-09-06 | Bristol-Myers Squibb Company | Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome |
| WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
| EP3692063A1 (en) * | 2017-10-03 | 2020-08-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| KR20210031482A (ko) * | 2018-07-13 | 2021-03-19 | 알렐 바이오테크놀로지 앤 파마슈티칼스, 인크. | 고-특이성의 게놈 편집을 달성하는 방법 |
| AU2020301025A1 (en) | 2019-07-03 | 2022-01-20 | Integrated Dna Technologies, Inc. | Identification, characterization, and quantitation of CRISPR-introduced double-stranded DNA break repairs |
| EP4048803A4 (en) * | 2019-10-24 | 2024-11-13 | Integrated Dna Technologies, Inc. | MODIFIED DOUBLE-STRANDED DONOR TEMPLATES |
| CN111549052A (zh) * | 2020-05-07 | 2020-08-18 | 西南大学 | 一种真核生物CRISPR/Cas全基因组编辑载体文库及构建方法 |
| JPWO2021251493A1 (enExample) * | 2020-06-12 | 2021-12-16 | ||
| CN111944847A (zh) * | 2020-08-28 | 2020-11-17 | 西北农林科技大学 | 一套等位基因高效替换系统及其建立方法 |
| CN113416730B (zh) * | 2021-07-07 | 2023-04-04 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 一种降低细胞因基因编辑产生的大片段删除突变的方法 |
| GB202117455D0 (en) * | 2021-12-02 | 2022-01-19 | Academisch Ziekenhuis Leiden | Method of editing nucleic acid |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| CA2186118C (en) | 1994-03-23 | 2010-10-19 | Richard W. Hanson | Compacted nucleic acids and their delivery to cells |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US8772008B2 (en) * | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
| BR112013001685B1 (pt) * | 2010-07-23 | 2021-10-13 | Sigma-Aldrich Co. Llc | Método para editar pelo menos uma sequência cromossômica endógena em uma célula pela inserção de uma sequência na sequência cromossômica |
| EP4019635A1 (en) | 2015-03-25 | 2022-06-29 | Editas Medicine, Inc. | Crispr/cas-related methods, compositions and components |
| EP3274453B1 (en) * | 2015-03-26 | 2021-01-27 | Editas Medicine, Inc. | Crispr/cas-mediated gene conversion |
| KR102888521B1 (ko) | 2015-04-06 | 2025-11-19 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna |
| US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
| EP3294896A1 (en) | 2015-05-11 | 2018-03-21 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| CN105734032A (zh) * | 2016-03-25 | 2016-07-06 | 扬州大学 | 一种山羊blg基因定点敲除修饰系统及应用 |
| EP3559230B1 (en) | 2016-12-20 | 2023-09-06 | Bristol-Myers Squibb Company | Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome |
-
2017
- 2017-12-20 EP EP17832436.4A patent/EP3559230B1/en active Active
- 2017-12-20 JP JP2019554497A patent/JP2020510443A/ja active Pending
- 2017-12-20 CN CN201780086730.XA patent/CN110300803B/zh active Active
- 2017-12-20 EP EP23188899.1A patent/EP4286523A3/en active Pending
- 2017-12-20 CN CN202410548057.9A patent/CN118460529A/zh active Pending
- 2017-12-20 KR KR1020197020845A patent/KR20190095412A/ko not_active Ceased
- 2017-12-20 US US16/471,680 patent/US20230193321A1/en active Pending
- 2017-12-20 KR KR1020237039262A patent/KR20230162134A/ko active Pending
- 2017-12-20 WO PCT/US2017/067569 patent/WO2018119060A1/en not_active Ceased
- 2017-12-20 ES ES17832436T patent/ES2962711T3/es active Active
-
2023
- 2023-10-11 JP JP2023176087A patent/JP2024009934A/ja active Pending
-
2025
- 2025-10-16 JP JP2025174888A patent/JP2026012785A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018119060A1 (en) | 2018-06-28 |
| US20230193321A1 (en) | 2023-06-22 |
| EP4286523A2 (en) | 2023-12-06 |
| KR20190095412A (ko) | 2019-08-14 |
| JP2020510443A (ja) | 2020-04-09 |
| CN110300803A (zh) | 2019-10-01 |
| CN110300803B (zh) | 2024-05-14 |
| JP2024009934A (ja) | 2024-01-23 |
| CN118460529A (zh) | 2024-08-09 |
| EP3559230B1 (en) | 2023-09-06 |
| JP2026012785A (ja) | 2026-01-27 |
| KR20230162134A (ko) | 2023-11-28 |
| EP4286523A3 (en) | 2024-03-20 |
| EP3559230A1 (en) | 2019-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3559230B1 (en) | Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome | |
| JP6993063B2 (ja) | ゲノムエンジニアリング | |
| US10526590B2 (en) | Compounds and methods for CRISPR/Cas-based genome editing by homologous recombination | |
| Pellagatti et al. | Application of CRISPR/Cas9 genome editing to the study and treatment of disease | |
| CN107208078B (zh) | 使用成对向导rna进行靶向遗传修饰的方法和组合物 | |
| JP2019193679A (ja) | 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物 | |
| EP3536796A1 (en) | Gene knockout method | |
| BR112019019655A2 (pt) | editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico | |
| WO2017024047A1 (en) | Compositions and methods for increasing nuclease induced recombination rate in cells | |
| JP2017536811A (ja) | 多能性細胞の樹立又は維持のための方法及び組成物 | |
| BR112017016080B1 (pt) | Polinucleotídeo crispr da classe 2 único, sistema crispr da classe 2 e método in vitro de modificação de uma molécula de ácido nucleico alvo em um organismo não-humano, ou em uma célula | |
| AU2014356400A1 (en) | Somatic haploid human cell line | |
| WO2016154579A2 (en) | Crispr/cas-mediated gene conversion | |
| JP6958917B2 (ja) | 遺伝子ノックイン細胞の作製方法 | |
| JP7210028B2 (ja) | 遺伝子変異導入方法 | |
| US20210403906A1 (en) | Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene | |
| Patmanathan et al. | CRISPR/Cas9 in stem cell research: current application and future perspective | |
| JP2020527938A (ja) | デザイナーｄｎａ組換え酵素を利用したゲノムを遺伝的に改変するための方法及び手段 | |
| CN113423831A (zh) | 核酸酶介导的重复扩增 | |
| JP7769691B2 (ja) | 新規の改良された塩基編集または編集用融合タンパク質およびその用途 | |
| EP4230737A1 (en) | Novel enhanced base editing or revising fusion protein and use thereof | |
| US20260132427A1 (en) | Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome | |
| WO2020036653A2 (en) | Improved method for homology directed repair in cells | |
| US20230295667A1 (en) | Use of anti-crispr agents to control editing in human embryos | |
| Jiang et al. | An in situ cut-and-paste genome editing platform mediated by CRISPR/Cas9 or Cas12a |